Preview Mode Links will not work in preview mode
Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show offers a glimpse into the latest innovations in applying generative AI, novel therapeutics and vaccines, and the evolving dynamics in the medical and healthcare landscape. One focus is on how providers, pharmaceutical companies, and payers are empowering patients.  In addition, conversations often focus on how technology is empowering providers, care facilities, pharmaceutical companies, and payers to improve patient outcomes and reduce friction across the healthcare landscape.  Popular Topics Include: Virtual and digital health Use of AI, ML, and robots for clinical and administrative purposes  Value-based healthcare  Precision and stratified medicine Next-generation immuno, cell, and gene therapies Vaccines for infectious diseases and oncology Biomarkers and diagnostics Rare diseases MedTech and medical devices Clinical trials  Population health Chronic conditions l Clinician and staff burnout Smart hospitals The audience includes life science leaders, researchers, medical professionals, patient advocates, digital health entrepreneurs, patients, caregivers, healthcare solution providers, students, journalists, and investors.

Oct 26, 2020

Rahul Aras, CEO, Iterion Therapeutics, describes their lead product Tegavivint, a potent selective inhibitor of nuclear beta-catenin, a high-value oncology target because of its role in cell proliferation, differentiation, immune evasion and other aspects of cancer development. An early clinical study in patients with the rare disease Desmoid tumors has showed that their tumor stabilized and reversed in size.  Progress is being driven by recent understanding of the role of TBL1 in driving oncogenic activity of beta-catenin.

#IterionTherapeutics #Tegavivint #cancer #DesmoidTumors #nuclearbetacatenin #TBL1

Iteriontherapeutics.com

Listen to the podcast here

Iterion